BACKGROUND AND AIMS: Evaluation of cytokeratin 20 (CK20) specific quantitative reverse transcriptase polymerase chain reaction (QRT-PCR) and immunohistochemistry (IHC) for detection of occult tumor cells in lymph nodes of 72 patients with colorectal carcinoma (UICC stage I and II). METHODS: Serial sections of formalin-fixed, paraffin-embedded lymph nodes (mean 14.3/case) were used for microdissection, RNA isolation and QRT-PCR and for CK20 IHC using routine protocols. Results of QRT-PCR and IHC were compared and correlated to the CK20 expression pattern of the primary tumors and clinical follow-up. RESULTS: IHC revealed CK20-positive tumor cells in lymph nodes of 14.5% (10/69) and 0% (0/3) cases with a CK20-positive and CK20-negative primary tumor, respectively. CK20 mRNA was detected in the lymph nodes of 36.8% (7/19) cases by QRT-PCR with all 7 cases also expressing CK20 mRNA in the primary tumor. CK20 mRNA (QRT-PCR) and protein (IHC) detection in serial sections did not agree in 25% (5/20) of cases. A trend was seen towards a worse disease course for patients with CK20-positive lymph nodes by IHC (incidence of recurrent disease) and QRT-PCR (disease-free survival, incidence of recurrent disease). CONCLUSION: CK20-specific IHC and QRT-PCR are supportive tools to conventional histology for detection of occult tumor cells in archival tissues, with the restriction that a laborious QRT-PCR procedure is necessary to achieve appropriate specificity. A prognostic value of CK20 IHC or QRT-PCR for stratification of UICC stage I and II patients into those likely to develop recurrent disease was not evident.
BACKGROUND AND AIMS: Evaluation of cytokeratin 20 (CK20) specific quantitative reverse transcriptase polymerase chain reaction (QRT-PCR) and immunohistochemistry (IHC) for detection of occult tumor cells in lymph nodes of 72 patients with colorectal carcinoma (UICC stage I and II). METHODS: Serial sections of formalin-fixed, paraffin-embedded lymph nodes (mean 14.3/case) were used for microdissection, RNA isolation and QRT-PCR and for CK20 IHC using routine protocols. Results of QRT-PCR and IHC were compared and correlated to the CK20 expression pattern of the primary tumors and clinical follow-up. RESULTS: IHC revealed CK20-positive tumor cells in lymph nodes of 14.5% (10/69) and 0% (0/3) cases with a CK20-positive and CK20-negative primary tumor, respectively. CK20 mRNA was detected in the lymph nodes of 36.8% (7/19) cases by QRT-PCR with all 7 cases also expressing CK20 mRNA in the primary tumor. CK20 mRNA (QRT-PCR) and protein (IHC) detection in serial sections did not agree in 25% (5/20) of cases. A trend was seen towards a worse disease course for patients with CK20-positive lymph nodes by IHC (incidence of recurrent disease) and QRT-PCR (disease-free survival, incidence of recurrent disease). CONCLUSION:CK20-specific IHC and QRT-PCR are supportive tools to conventional histology for detection of occult tumor cells in archival tissues, with the restriction that a laborious QRT-PCR procedure is necessary to achieve appropriate specificity. A prognostic value of CK20 IHC or QRT-PCR for stratification of UICC stage I and II patients into those likely to develop recurrent disease was not evident.
Authors: Y Miyake; H Yamamoto; Y Fujiwara; M Ohue; Y Sugita; N Tomita; M Sekimoto; N Matsuura; H Shiozaki; M Monden Journal: Clin Cancer Res Date: 2001-05 Impact factor: 12.531
Authors: M Sanchez-Cespedes; M Esteller; K Hibi; F O Cope; W H Westra; S Piantadosi; J G Herman; J Jen; D Sidransky Journal: Clin Cancer Res Date: 1999-09 Impact factor: 12.531
Authors: R Moll; R Zimbelmann; M D Goldschmidt; M Keith; J Laufer; M Kasper; P J Koch; W W Franke Journal: Differentiation Date: 1993-06 Impact factor: 3.880
Authors: D K Wyld; P Selby; T J Perren; S K Jonas; T G Allen-Mersh; J Wheeldon; S A Burchill Journal: Int J Cancer Date: 1998-06-19 Impact factor: 7.396
Authors: R A Ghossein; H I Scher; W L Gerald; W K Kelly; T Curley; A Amsterdam; Z F Zhang; J Rosai Journal: J Clin Oncol Date: 1995-05 Impact factor: 44.544
Authors: D S Hoon; Y Wang; P S Dale; A J Conrad; P Schmid; D Garrison; C Kuo; L J Foshag; A J Nizze; D L Morton Journal: J Clin Oncol Date: 1995-08 Impact factor: 44.544
Authors: Giuliana Giribaldi; Simone Procida; Daniela Ulliers; Franca Mannu; Roberta Volpatto; Giorgia Mandili; Laura Fanchini; Oscar Bertetto; Gianruggero Fronda; Luigi Simula; Elena Rimini; Giovanni Cherchi; Lisa Bonello; Milena Maria Maule; Francesco Turrini Journal: J Mol Diagn Date: 2006-02 Impact factor: 5.568
Authors: Sze Chuen Cesar Wong; Moon Tong Cheung; Lewis Lai Yin Luk; Vivian Ha Man Lee; Pak Tat Chan; Hin Fung Andy Tsang; Evelyn Yin Kwan Wong; Vivian Weiwen Xue; Amanda Kit Ching Chan; John Kwok Cheung Chan Journal: Oncotarget Date: 2017-12-19
Authors: J Harder; V Engelstaedter; H Usadel; S Lassmann; M Werner; P Baier; F Otto; M Varbanova; E Schaeffner; M Olschewski; H E Blum; O G Opitz Journal: Br J Cancer Date: 2009-01-13 Impact factor: 7.640